The Chemotherapy Induced Oral Mucositis drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Oral Mucositis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Oral Mucositis and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Chemotherapy Induced Oral Mucositis by eight companies/universities/institutes. The top development phase for Chemotherapy Induced Oral Mucositis is phase ii with five drugs in that stage. The Chemotherapy Induced Oral Mucositis pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chemotherapy Induced Oral Mucositis pipeline products market are: Maruho, Tosk and Innovation Pharmaceuticals.
The key targets in the Chemotherapy Induced Oral Mucositis pipeline products market include Histone Deacetylase, Bacterial Cell Membrane, and Uridine Phosphorylase.
The key mechanisms of action in the Chemotherapy Induced Oral Mucositis pipeline product include Histone Deacetylase Inhibitor with one drug in Phase II. The Chemotherapy Induced Oral Mucositis pipeline products include six routes of administration with the top ROA being Oral and one key molecule types in the Chemotherapy Induced Oral Mucositis pipeline products market including Small Molecule.
Chemotherapy Induced Oral Mucositis overview
Oral mucositis is an inflammation of oral mucosa most commonly occurs after chemotherapy. It is an adverse effect associated with chemotherapy and most found in patients on chemo regimen. Cytotoxic damage to the submucosal cells causes mucositis. It occurs generally after 1 week of chemo and 2 weeks after radiation therapy. It can spread from mouth to anu affecting the whole GI tract and at increased risk of developing infections. Dry mouth, sore throat, mouth ulcers, oral thrush are common symptoms. Infection if spreads to GI tract diarrhea, vomiting, abdominal cramps are seen. Uncomplicated cases requires supportive therapy while in other cases topical anesthetics to relieve pain, normal saline, salt based mouth washes to keep hygienic.
For a complete picture of Chemotherapy Induced Oral Mucositis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
